India Updates Import Rules to Boost Pharmaceutical Supply Chain Efficiency

The Union Health Ministry has introduced a draft notification proposing a major shift in how imported drugs are regulated. The proposal seeks to replace the current requirement of 60% residual shelf life with a fixed minimum of 12 months at the time of import. This change is designed to improve efficiency in the pharmaceutical supply chain and reduce the wastage of imported medicines that currently struggle to meet the percentage-based criteria.

Recognizing the unique requirements of certain medical products, the Ministry has clarified that the existing 60% residual shelf life requirement will remain in effect for biological products and radiopharmaceuticals. These items require specialized handling and have shorter stability windows, making a fixed 12-month rule impractical. This nuanced approach ensures that the policy balances the need for supply chain fluidity with the necessity of maintaining high safety standards for sensitive medical goods.

The Ministry has invited public comments on these draft amendments to the Drugs Rules, 1945. This consultative process is critical for ensuring that the final regulations are practical for importers while maintaining the integrity of the Indian drug market. By modernizing these rules, the government aims to ensure the continued availability of high-quality medicines, particularly for treatments that rely on international supply chains. The outcome of this consultation will likely set the standard for pharmaceutical import regulations for the coming years.